What’s Holding Back mRNA-LNP Therapeutics?

Managing Purity and Impurity

Given the complex, multi-component nature of mRNA/LNP therapeutics, maintaining high product purity is essential. This requires careful monitoring and characterization of impurities to ensure therapeutic efficacy.

Challenges Related to mRNA Payload:

Double-Stranded RNA (dsRNA): This impurity, generated during in vitro transcription (IVT), can trigger undesirable immune responses, compromising safety and efficacy. Efficient removal remains a major purification challenge.

Truncated and Degraded mRNA: The fragile nature of mRNA makes it prone to fragmentation and degradation throughout IVT, purification, and LNP formulation. Separating intact mRNA from fragments is crucial to ensure product quality.

IVT Byproducts: Impurities such as DNA templates and unincorporated nucleotides must be eliminated for clinical-grade purity.

Our Solutions:

• dsRNA removal: Can be achieved using reversed-phase chromatography, which employs organic solvents to effectively separate molecules based on length. For facilities unable to use organic solvents, an innovative technique is available that utilizes hydrogen bonding principles combined with monolithic columns for affinity-based mRNA capture. Read this blog for more information on this important topic.
• For truncated and degraded mRNA, there is an established chromatographic method embedded within an analytical platform specifically designed for monitoring and purifying mRNA. This method is comparable to capillary gel electrophoresis (CGE), providing a faster and more cost-effective solution.
• IVT byproducts: Using multimodal chromatography monolith columns within the mRNA analytical platform, impurities can be quantified in under 10 minutes.

Challenges Related to LNP Formulation:

Non-encapsulated/free mRNA: Ensuring high encapsulation efficiency (EE%) is vital to prevent degradation and immune reactions, necessitating removal during purification.

Empty Liposomes/LNPs: Compete with functional LNPs for uptake, requiring effective separation to maintain drug efficacy.

Solvents and Raw Material Purity: Ethanol and lipid component purity impact final product quality, presenting challenges in maintaining purity at large scales.

Our Solutions:

• Hydrophobic interaction monolithic chromatography efficiently removes solvents and free mRNA, enhancing LNP purification.
• Our analytical platform, dedicated to LNP characterization enables precise, real-time characterization of LNP formulations, assessing integrity, stability, and performance.

Process Monitoring and Characterization

Robust analytical methods are vital for LNP-mRNA stability, yet traditional batch analytics often fall short, especially for real-time, in-line process control.

Limitations of Traditional Batch Analytics:

Speed and Relevance: Offline methods like Dynamic Light Scattering (DLS) delay results, impacting real-time control and potentially leading to waste.

Sample Heterogeneity: Batch methods struggle to accurately characterize LNP subpopulations, providing average measurements that obscure critical differences.

LNP Disruption: Necessary for purity analysis, this offline step can degrade mRNA and introduce measurement uncertainties.

Sub-populations: Fast, reliable methods are needed to monitor and characterize LNP subpopulations during manufacturing.

The Need for Advanced Monitoring (PAT):

Real-Time Critical Quality Attribute (CQA) Monitoring: Process Analytical Technology (PAT) tools enable continuous manufacturing by monitoring CQAs in-line or at-line, focusing on parameters like particle size, EE%, and mRNA integrity.

Our Solutions:

• Analytical platform, dedicated to LNP characterization: Offers multiparameter insights into CQAs, supporting applications in CRISPR, CAR-T, and combination vaccines, enhancing process monitoring and quality control.

Scalability and Consistency

Scaling up from lab production to commercial manufacturing introduces challenges, particularly regarding process consistency.

Challenges:

Shear Sensitivity: LNPs are vulnerable to shear stress during purification steps like Tangential Flow Filtration (TFF), affecting safety and efficacy. Minimizing damage and aggregation during scale-up is critical.

Continuous Manufacturing: Integrating synthesis, LNP formation, purification, and sterile filtration into a continuous flow presents complex engineering challenges.

Non-Standardized Processes: Unlike monoclonal antibodies, the LNP-mRNA field lacks standardized purification processes, requiring costly redevelopment for each new formulation.

Our Solutions:

• Hydrophobic interaction monolithic chromatography: Maintains LNP integrity by eliminating shear stress, ensuring efficient purification and high in vitro activity. High encapsulation efficiency, recovery, activity, and uniform particle size are consistently achieved across scales, as confirmed at large scale.

This exploration of mRNA/LNP therapeutics highlights the challenges and solutions in the field, emphasizing the importance of advanced techniques and real-time monitoring for successful bioprocessing. By addressing these issues, the industry moves closer to producing safer, more effective therapies for everyone.